These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39020195)

  • 21. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.
    Turton S; Nutt DJ; Carhart-Harris RL
    Curr Drug Abuse Rev; 2014; 7(2):117-27. PubMed ID: 25563444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sixty seconds on . . . psilocybin.
    Hawkes N
    BMJ; 2016 May; 353():i2775. PubMed ID: 27194646
    [No Abstract]   [Full Text] [Related]  

  • 23. Bridging Psilocybin-Induced Changes in the Brain's Dynamic Functional Connectome With an Individual's Subjective Experience.
    Singleton SP; Kuceyeski A
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 Jul; 9(7):637-638. PubMed ID: 38969436
    [No Abstract]   [Full Text] [Related]  

  • 24. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention.
    Barrett FS; Krimmel SR; Griffiths RR; Seminowicz DA; Mathur BN
    Neuroimage; 2020 Sep; 218():116980. PubMed ID: 32454209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.
    Kometer M; Pokorny T; Seifritz E; Volleinweider FX
    Psychopharmacology (Berl); 2015 Oct; 232(19):3663-76. PubMed ID: 26231498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future.
    Nutt D
    J Psychopharmacol; 2016 Dec; 30(12):1163-1164. PubMed ID: 27909163
    [No Abstract]   [Full Text] [Related]  

  • 27. Return of the psychedelics: Psilocybin for treatment resistant depression.
    Patra S
    Asian J Psychiatr; 2016 Dec; 24():51-52. PubMed ID: 27931907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia.
    Strauss N
    Med J Aust; 2017 Jun; 206(11):468-469. PubMed ID: 28918722
    [No Abstract]   [Full Text] [Related]  

  • 29. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
    Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
    Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for 'hallucinogens'.
    Koerner J; Appel JB
    Psychopharmacology (Berl); 1982; 76(2):130-5. PubMed ID: 6805022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reviving the study of hallucinogens.
    Harv Ment Health Lett; 2006 Oct; 23(4):5. PubMed ID: 17183740
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pharmacological action spectra of hallucinogens].
    Waser PG
    Bull Schweiz Akad Med Wiss; 1971 Jun; 27(1):39-57. PubMed ID: 5141141
    [No Abstract]   [Full Text] [Related]  

  • 33. Do the therapeutic effects of psilocybin involve actions in the gut?
    Reed F; Foldi CJ
    Trends Pharmacol Sci; 2024 Feb; 45(2):107-117. PubMed ID: 38216431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The possible role of tryptamine in brain function and its relationship to the actions of LSD-like hallucinogens.
    Martin WR; Sloan JW
    Mt Sinai J Med; 1974; 41(2):276-82. PubMed ID: 4544624
    [No Abstract]   [Full Text] [Related]  

  • 35. Increased activation of indirect semantic associations under psilocybin.
    Spitzer M; Thimm M; Hermle L; Holzmann P; Kovar KA; Heimann H; Gouzoulis-Mayfrank E; Kischka U; Schneider F
    Biol Psychiatry; 1996 Jun; 39(12):1055-7. PubMed ID: 8780843
    [No Abstract]   [Full Text] [Related]  

  • 36. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.
    Grimm O; Kraehenmann R; Preller KH; Seifritz E; Vollenweider FX
    Eur Neuropsychopharmacol; 2018 Jun; 28(6):691-700. PubMed ID: 29703645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.
    Meccia J; Lopez J; Bagot RC
    Psychopharmacology (Berl); 2023 Jan; 240(1):27-40. PubMed ID: 36564671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psilocybin: a pharmacological profile.
    Aboul-Enein HY
    Am J Pharm Sci Support Public Health; 1974; 146(3):91-5. PubMed ID: 4853936
    [No Abstract]   [Full Text] [Related]  

  • 39. Psilocybin-assisted therapy for depression: How do we advance the field?
    Meikle SE; Liknaitzky P; Rossell SL; Ross M; Strauss N; Thomas N; Murray G; Williams M; Castle DJ
    Aust N Z J Psychiatry; 2020 Mar; 54(3):225-231. PubMed ID: 31752499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.
    Vollenweider FX
    Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():92-103. PubMed ID: 9754840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.